查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
高血鉀症市場 - 全球及區域 - 分析與預測（2025-2035）
市場調查報告書
商品編碼
1759278

高血鉀症市場 - 全球及區域 - 分析與預測（2025-2035）

Hyperkalemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

高血鉀症是一種以血液中鉀含量升高為特徵的疾病。

鉀是人體必需的電解質，有助於調節重要的身體功能，包括神經傳遞、肌肉收縮和體液平衡。但是，如果鉀水平過高，則會導致嚴重的健康問題，尤其會對心臟產生影響。高血鉀最常見的原因是腎功能受損，因為腎臟負責從血液中過濾多餘的鉀。慢性腎臟病(CKD)、心臟衰竭和糖尿病等疾病會降低腎功能並增加高血鉀的風險。使用某些可升高鉀水平的藥物也可能導致高血鉀症，例如 RAAS 抑制劑（ACE 抑制劑、ARB）和保鉀利尿劑。高血鉀的症狀包括肌肉無力、疲勞、心律不整，嚴重的情況下心臟麻痹。需要立即治療以控制病情並預防危及生命的併發症。

高血鉀市場的主要促進因素之一是慢性腎臟病(CKD) 盛行率的上升。隨著全球人口老化，CKD 盛行率也隨之上升，增加了高血鉀的風險。 CKD 會導致腎功能逐漸衰退，削弱腎臟過濾並排出體內過量鉀的能力。這會導致鉀在血液中積聚，引發高血鉀症。此外，CKD 患者通常使用 RAAS 抑制劑（例如 ACE 抑制劑、ARB 和醛固酮拮抗劑）來控制病情，而這會進一步升高血鉀水平。隨著全球 CKD 患者數量的增加，對有效治療高血鉀症的治療需求顯著增加，這推動了市場的成長。此外，心臟衰竭和糖尿病盛行率的上升（這些也是高血鉀的誘因）也進一步推動了該市場的成長。

儘管高血鉀市場正在成長，但仍有若干挑戰阻礙其發展。主要挑戰之一是治療費用高昂，尤其是像 Veltassa（patiromer）和 Lokelma（環矽酸鋯鈉）等鉀粘合劑這樣的較新治療方法。這些療法費用高昂，難以取得，尤其是對於低收入地區和醫療保險有限的患者。慢性腎臟病(CKD) 和心臟衰竭等慢性病的持續治療費用給醫療保健系統和患者帶來了沉重的經濟負擔，降低了這些治療方法的整體應用率。此外，一些降鉀藥物的副作用，如胃腸不適（如便秘、腹瀉、腹痛），會影響患者的依從性並影響治療方法的有效性。儘管對有效解決方案的需求日益成長，但這些因素阻礙了高血鉀管理策略的廣泛實施。

全球高血鉀市場競爭激烈，多家主要企業推動創新和市場成長。賽諾菲、Ardelyx、阿斯特捷利康、Vifor Pharma 和禮來公司等公司處於開發和提供高血鉀治療方法的前沿。賽諾菲的 Veltassa（patiromer）在治療慢性高鉀血症方面發揮關鍵作用，尤其是對於患有慢性腎臟病(CKD) 和心臟衰竭的患者。 Ardelyx 擁有創新的高血鉀治療藥物 Tenapanor，而Astra Zeneca提供 Lokelma（環矽酸鋯鈉），這是一種口服鉀粘合劑，對急性和慢性高鉀血症均有效。禮來公司也持續為市場提供針對腎臟病和心臟衰竭等相關疾病的廣泛治療組合。這些公司正在努力擴大治療選擇的管道，並開發新的治療方法，以滿足全球 CKD 和心臟衰竭發病率上升以及人口老齡化導致高鉀血症患者數量不斷增加所帶來的日益成長的需求。

市場區隔

細分一：按地區

  • 北美洲
  • 歐洲
  • 亞太地區

全球高血鉀市場正經歷重大變革時期，其驅動力源自於重塑治療和管理策略的新興趨勢。推動這項變革的關鍵趨勢之一是對創新鉀結合療法的日益關注，例如 Veltassa（帕替羅莫）和 Lokelma（環矽酸鋯鈉），這些療法為慢性和急性高鉀血症的治療提供了更有效、更安全的解決方案。這些新療法旨在應對日益成長的高血鉀盛行率，尤其是在患有慢性腎臟病(CKD)、心臟衰竭以及服用可升高鉀水平的 RAAS 抑制劑的患者中。

另一個新興趨勢是個人化醫療的興起，旨在根據患者的特定醫療狀況和遺傳因素，為其量身定做治療方案。這種方法可以提高治療效果，改善患者預後。此外，數位醫療工具和遠端患者監護的日益普及，使醫療保健提供者能夠即時追蹤患者鉀水平，從而改善高血鉀的管理並減少住院治療。隨著各公司不斷創新，並提高高血鉀治療的可近性，尤其是在需求旺盛的未開發地區，這一趨勢有望推動市場持續成長。

本報告研究了全球高血鉀市場，並概述了市場以及區域趨勢和公司概況。

目錄

執行摘要

第1章全球高血鉀市場：產業展望

  • 介紹
  • 市場趨勢
  • 法律規範
  • 流行病學分析
  • 臨床試驗分析
  • 市場動態

2. 2023-2035 年全球高血鉀症市場（按地區）

  • 北美洲
  • 歐洲
  • 亞太地區

3. 全球高血鉀市場：競爭格局與公司概況

  • 關鍵策略和發展
    • 合併與收購
    • 協同活動
    • 業務擴展和資金籌措
    • 產品發布和核准
    • 其他活動
  • 公司簡介
    • Sanofi
    • Ardelyx
    • AstraZeneca
    • Vifor Pharma (Zeria Pharmaceutical)
    • Eli Lilly and Company
    • Novo Nordisk
    • Zynteglo (Bluebird Bio)
    • Novartis AG

第4章調查方法

Product Code: BHL3074SA

Global Hyperkalemia Market, Analysis and Forecast: 2025-2035

Hyperkalemia is a medical condition characterized by elevated levels of potassium in the blood. Potassium is an essential electrolyte that helps regulate important bodily functions, including nerve transmission, muscle contraction, and fluid balance. However, when potassium levels become too high, it can lead to serious health issues, particularly affecting the heart. Hyperkalemia is most caused by kidney dysfunction, as the kidneys are responsible for filtering excess potassium from the blood. Conditions like chronic kidney disease (CKD), heart failure, and diabetes can impair kidney function and increase the risk of hyperkalemia. It can also result from the use of certain medications like RAAS inhibitors (ACE inhibitors, ARBs) or potassium-sparing diuretics, which may elevate potassium levels. Symptoms of hyperkalemia include muscle weakness, fatigue, irregular heartbeats, and in severe cases, cardiac arrest. Immediate treatment is necessary to manage the condition and prevent life-threatening complications.

One of the key drivers of the Hyperkalemia market is the rising prevalence of chronic kidney disease (CKD). As the global population ages, the incidence of CKD increases, which in turn raises the risk of hyperkalemia. CKD leads to a gradual decline in kidney function, impairing the kidneys' ability to filter and excrete excess potassium from the body. This results in an accumulation of potassium in the bloodstream, causing hyperkalemia. Moreover, CKD patients are often treated with RAAS inhibitors (such as ACE inhibitors, ARBs, and aldosterone antagonists) to manage their condition, which can further increase potassium levels. With the growing number of CKD patients worldwide, there is a significant rise in the demand for treatments that effectively manage hyperkalemia, driving market growth. Additionally, the rising prevalence of heart failure and diabetes, conditions that also contribute to hyperkalemia, further supports this market growth.

Despite the growth of the Hyperkalemia market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment, particularly for newer therapies such as potassium binders like Veltassa (patiromer) and Lokelma (sodium zirconium cyclosilicate). These treatments can be expensive, making them less accessible, especially in low-income regions or for patients with limited healthcare coverage. The cost of ongoing treatment for chronic conditions like chronic kidney disease (CKD) and heart failure can place a significant financial burden on healthcare systems and patients, reducing the overall adoption of these therapies. Additionally, the side effects associated with some potassium-lowering medications, such as gastrointestinal discomfort (e.g., constipation, diarrhea, and abdominal pain), can affect patient compliance and impact the effectiveness of treatment regimens. These factors contribute to barriers in the broader implementation of hyperkalemia management strategies, despite the rising demand for effective solutions.

The global Hyperkalemia market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Sanofi, Ardelyx, AstraZeneca, Vifor Pharma, and Eli Lilly and Company are at the forefront of developing and offering treatments for hyperkalemia. Sanofi, with its Veltassa (patiromer), has been a significant player in managing chronic hyperkalemia, especially in patients with chronic kidney disease (CKD) and heart failure. Ardelyx is innovating with its drug Tenapanor, designed to treat hyperkalemia, while AstraZeneca offers Lokelma (sodium zirconium cyclosilicate), an effective oral potassium binder for both acute and chronic hyperkalemia. Vifor Pharma, in partnership with Zeria Pharmaceutical, provides essential therapies for patients with renal diseases, while Eli Lilly and Company continues to contribute to the market with its broad portfolio of treatments for related conditions like kidney disease and heart failure. These companies are not only advancing new therapies but are also working to expand access to treatment options, meeting the increasing demand driven by rising cases of hyperkalemia due to the global increase in CKD, heart failure, and an aging population.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Hyperkalemia market is undergoing significant transformation, fueled by emerging trends that are reshaping the landscape of treatment and management strategies. One of the key trends driving this change is the increased focus on innovative potassium-binding therapies, such as Veltassa (patiromer) and Lokelma (sodium zirconium cyclosilicate), which offer more effective and safer solutions for managing both chronic and acute hyperkalemia. These newer treatments are designed to address the growing prevalence of hyperkalemia, particularly in patients with chronic kidney disease (CKD), heart failure, and those on RAAS inhibitors that increase potassium levels.

Another emerging trend is the rise of personalized medicine, which aims to tailor treatment plans to individual patient needs based on specific conditions and genetic factors. This approach enhances treatment efficacy and improves patient outcomes. Additionally, there is an increased emphasis on digital health tools and remote patient monitoring, allowing healthcare providers to track potassium levels in real-time, thereby improving the management of hyperkalemia and reducing hospitalizations. With these trends, the market is poised for continued growth as companies innovate and improve accessibility to hyperkalemia treatments, particularly in underserved regions with rising healthcare demands.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Hyperkalemia Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Hyperkalemia Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Hyperkalemia Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Hyperkalemia Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Hyperkalemia Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Hyperkalemia Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Sanofi
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Ardelyx
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 AstraZeneca
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Vifor Pharma (Zeria Pharmaceutical)
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Eli Lilly and Company
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Novo Nordisk
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
    • 3.2.7 Zynteglo (Bluebird Bio)
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Novartis AG
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Hyperkalemia Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Hyperkalemia Market Key Trends, Analysis

List of Tables

  • Table: Global Hyperkalemia Market Dynamics, Impact Analysis
  • Table: Global Hyperkalemia Market (by Region), $Billion, 2024-2035